Last reviewed · How we verify
NCT05874674: Nafamostat
The Safety of Nafamostat Mesylate for Patients With High Risk Bleeding Undergoing Hemodialysis: A Pilot Study
NA trial testing Nafamostat Mesylate in Dialysis; Complications in 100 participants. Currently enrolling.
31 December 2025
Quick facts
| Lead sponsor | Wonju Severance Christian Hospital |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | prevention |
| Enrollment | 100 |
| Start date | 1 December 2023 |
| Primary completion | 31 December 2025 |
| Estimated completion | 31 December 2026 |
| Sites | 1 location across South Korea |
Drugs / interventions tested
- Nafamostat Mesylate — full drug profile →
Conditions studied
- Dialysis; Complications — all drugs for Dialysis; Complications →
- Bleeding — all drugs for Bleeding →
Sponsor
Wonju Severance Christian Hospital
Who can join
Adults 18 to 99, any sex, with Dialysis; Complications or Bleeding. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Comparison nafamostat and low molecular weight heparin among dialysis patients
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Anticoagulation for people receiving long-term haemodialysis.
Natale P, Palmer SC, Ruospo M, Longmuir H, et al · · 2024 · cited 10× · PMID 38189593 · DOI 10.1002/14651858.cd011858.pub2
Verify or expand the search:
- PubMed search for NCT05874674
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Nafamostat Mesylate
Trials testing the same drug.
- NCT07518303 — Nafamostat Mesylate Versus Regional Citrate Anticoagulation for Continuous Renal Replacement Therapy in Sepsis-Associate · Phase 4 · not yet recruiting
- NCT06994312 — The Impact of Nafamostat Mesylate on the Prognosis of Patients With Sepsis-Induced Coagulopathy Undergoing Hemofiltratio · NA · not yet recruiting
- NCT06500793 — Single Dose Study, Pharmacokinetics of Oxycodone and PF614 Co-Administered With Nafamostat (PF614-MPAR-102) · Phase 1 · recruiting
- NCT05555641 — Efficacy and Safety of Nafamostat Mesylate for VV-ECMO Anticoagulation · Phase 2 · unknown
- NCT05090280 — Pharmacokinetics of Oxycodone and PF614 Co-Administered with Nafamostat (PF614-MPAR-101) · Phase 1 · completed
Other recruiting trials for Dialysis; Complications
Currently open trials in the same condition.
- NCT07412834 — Safely Disconnect From the Dialysis Machine in an Emergency Situation · active not recruiting
- NCT03629977 — Timing of Renal Replacement Therapy in the Critically Ill Patients · recruiting
- NCT07045155 — Pegmolesatide Treatment for Anemia in Patients Undergoing Long-term Dialysis · Phase 4 · recruiting
- NCT05490225 — Access Cannulation Trial II · NA · recruiting
- NCT05418647 — Effect of Low Versus High Dialysate Sodium Concentration During Hemodialysis on Dialysis Recovery Time · NA · recruiting
Other Wonju Severance Christian Hospital trials
Trials by the same sponsor.
- NCT07012499 — QOL and Mental Health Using APD With Remote Monitoring System · NA · enrolling by invitation
- NCT07146178 — Long-term Follow-up of Bio-signals and Quality of Recovery Following Implementation of ERAS · NA · not yet recruiting
- NCT06675396 — Pharmacogenomics of Mood Disorder in Chronic Kidney Disease Patients · not yet recruiting
- NCT06540430 — Digital Based Home Care Service for Ostomy Patients · NA · not yet recruiting
- NCT07017088 — Efficacy of Leuconostoc Mesenteroides · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05874674 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Wonju Severance Christian Hospital
- Last refreshed: 30 July 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05874674.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing